Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.

Anavex President & CEO Christopher U. Missling, PhD, will be presenting preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19, 2017. May 17-19, 2017 | Turnberry Isle Miami Hotel  | Aventura, Florida Antiepileptic Drug Trials XIV Conference | May 2017 Friday, May 19, 2017 3:10pm ET ANAVEX 2-73, A…

Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21.

Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World  Orphan Drug Congress USA, Friday, at 12:20 PM on April 21. Wardmar Park Marriott Washington, DC Roundtable 4: Partnerships- successful collaboration between a rare disease foundation and a pharmaceutical company to advance preclinical and clinical research in Rett…

Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017

NEW YORK, March 29, 2017 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announced today data presentations related to Anavex’s Alzheimer’s disease pipeline…

Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference

NEW YORK — March 15, 2017 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…

Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference

NEW YORK – March 13, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…

BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”

Event:   BIO CEO & Investor Conference 2017 Date/Time:      Tuesday, February 14, 2017 from 2:30 p.m. to 3:25 p.m. Eastern Time Location:         The Waldorf Astoria Hotel in New York, NY https://www.bio.org/events/bio-ceo-investor-conference Christopher U. Missling, PhD, President and Chief Executive Officer will participate on the panel titled “Designing Clinical Trials in a 21st Century Cures…